SOUTH SAN FRANCISCO, CA, DiCE Molecules announced the completion of an $80 million Series C financing led by RA Capital Management.
DiCE Molecules announced the completion of an $80 million Series C financing. The financing was led by RA Capital Management with participation from new investors including Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Osage University Partners and Asymmetry Capital Management. Existing investors Northpond Ventures, Sands Capital, Sanofi Ventures, Alexandria Venture Investments, Altitude Life Science Ventures and Agent Capital also participated.
DiCE Molecules is a biotechnology company utilizing its proprietary DNA-encoded library (DEL) technology, combined with unique structural insights, to generate small molecule antagonists against a range of protein-protein-interface (PPI) targets.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about